Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

References

• American Cancer Society. Cancer Facts & Figures. Vol. 1; 2019:219
   Google Scholar
• Ferrara R, Mezquita L, Besse B. Progress in the management of advanced thoracic malignancies in 2017. J Thorac Oncol. 2018;13(3):301–322. doi:10.1016/j.jtho.2018.01.00229331646
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006. doi:10.1001/jama.2014.374124846037
   PubMed Web of Science ®Google Scholar
• Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1416–1423. doi:10.1097/JTO.0b013e3181da36f420686429
   PubMed Web of Science ®Google Scholar
• Zhang H, Huang Z, Zou X, et al. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2016;7(50):82473–82481. doi:10.18632/oncotarget.1266627756883
   PubMedGoogle Scholar
• Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227–1234. doi:10.1200/JCO.2007.14.546619188680
   PubMed Web of Science ®Google Scholar
• Tsironis G, Ziogas DC, Kyriazoglou A, et al. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore? Ann Transl Med. 2018;6(8):143. doi:10.21037/atm2018.02.1829862232
   PubMed Web of Science ®Google Scholar
• Barlesi F, Scherpereel A, Gorbunova V, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014;25(5):1044–1052. doi:10.1093/annonc/mdu09824585722
   PubMed Web of Science ®Google Scholar
• Alshangiti A, Chandhoke G, Ellis PM. Antiangiogenic therapies in non-small-cell lung cancer. Curr Oncol. 2018;25(Suppl 1):S45–S58. doi:10.3747/co.25.374729910647
   PubMedGoogle Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous Non–small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi:10.1056/NEJMoa181086530280635
   PubMed Web of Science ®Google Scholar
• Crino L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 2010;11(8):733–740. doi:10.1016/S1470-2045(10)70151-020650686
   PubMed Web of Science ®Google Scholar
• Lynch TJ Jr, Spigel DR, Brahmer J, et al. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. J Thorac Oncol. 2014;9(9):1332–1339. doi:10.1097/JTO.000000000000025725122429
   PubMed Web of Science ®Google Scholar
• Piperdi B, Merla A, Perez-Soler R. Targeting angiogenesis in squamous non-small cell lung cancer. Drugs. 2014;74(4):403–413. doi:10.1007/s40265-014-0182-z24578213
   PubMed Web of Science ®Google Scholar
• Sheng J, Yang Y, Ma Y, et al. The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0127306. doi:10.1371/journal.pone.012730626034985
   PubMed Web of Science ®Google Scholar
• Clement-Duchene C, Godbert B, Martinet Y. Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities. Rev Mal Respir. 2012;29(2):161–177. doi:10.1016/j.rmr.2011.06.01722405111
   PubMed Web of Science ®Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(S4):iv192–iv237.30285222
   PubMedGoogle Scholar
• Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19(3):851–856. doi:10.1200/JCO.2001.19.3.85111157039
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–2191. doi:10.1200/JCO.2004.11.02215169807
   PubMed Web of Science ®Google Scholar
• Cortot A, Audigier-Valette C, Molinier O, et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): results from the phase III study IFCT-1103 ULTIMATE. J Clin Oncol. 2016;34(15):9005. doi:10.1200/JCO.2016.34.15_suppl.9005
   Web of Science ®Google Scholar
• Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763–774. doi:10.1016/S1470-2045(15)00021-226045340
   PubMed Web of Science ®Google Scholar
• Reck M, Paz-Ares L, Bidoli P, et al. Outcomes in patients with aggressive or refractory disease from REVEL: a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer. 2017;112(11):181–187. doi:10.1016/j.lungcan.2017.07.03829191593
   PubMedGoogle Scholar
• Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–673. doi:10.1016/S0140-6736(14)60845-X24933332
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–155. doi:10.1016/S1470-2045(13)70586-224411639
   PubMed Web of Science ®Google Scholar
• Reck M, Barlesi F, Crino L, et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol. 2012;23(5):1111–1120. doi:10.1093/annonc/mdr46322056855
   PubMed Web of Science ®Google Scholar
• Barlesi F, Balleyguier C, Besse B, et al. Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Ann Oncol. 2010;21(8):1682–1686. doi:10.1093/annonc/mdp59020064831
   PubMed Web of Science ®Google Scholar
• Lunacsek OE, Ravelo A, Coutinho AD, et al. First line treatment with bevacizumab and platinum doublet combination in non squamous non small cell lung cancer: a retrospective cohort study in US oncology community practices. Real World Outcomes. 2016;3(3):333–343. doi:10.1007/s40801-016-0090-5
   PubMedGoogle Scholar
• Nadler E, Forsyth M, Satram-Hoang S, Reye C. Costs and clinical outcomes among patients with second line non small cell lung cancer in the outpatient community setting. J Thorac Oncol. 2012;7(1):212–218. doi:10.1097/JTO.0b013e3182307f3322124474
   PubMed Web of Science ®Google Scholar
• Arunachalam A, Li H, Bittoni MA, et al. Real world treatment patterns, overall survival and occurrence and costs of adverse events associated with second line therapies for Medicare patients with advanced non small cell lung cancer. Clin Lung Cancer. 2018;19(5):e783–e799. doi:10.1016/j.cllc.2018.05.01629983370
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol. 2012;30(25):3084–3092. doi:10.1200/JCO.2011.39.764622851564
   PubMed Web of Science ®Google Scholar
• Bondarenko IM, Ingrosso A, Bycott P, Kim S, Cebotaru CL. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer. BMC Cancer. 2015;15:339. doi:10.1186/s12885-015-1350-625929582
   PubMed Web of Science ®Google Scholar
• Heist RS, Wang X, Hodgson L, et al. CALGB 30704 (Alliance): a randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9(2):214–221. doi:10.1097/JTO.000000000000007124419419
   PubMed Web of Science ®Google Scholar
• Herbst RS, Sun Y, Eberhardt WE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010;11(7):619–626. doi:10.1016/S1470-2045(10)70132-720570559
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Fang L, Huang JE, et al. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol. 2011;6(1):109–114. doi:10.1097/JTO.0b013e3181f94ad421107290
   PubMed Web of Science ®Google Scholar
• Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G. Bevacizumab in advanced lung cancer: state of the art. Future Oncol. 2017;13(28):2515–2535. doi:10.2217/fon-2017-030228812378
   PubMed Web of Science ®Google Scholar
• Russo AE, Priolo D, Antonelli G, et al. Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer (Auckl). 2017;8(12):259–269. doi:10.2147/LCTT.S11030629276417
   PubMedGoogle Scholar
• Das M, Wakelee H. Targeting VEGF in lung cancer. Expert Opin Ther Targets. 2012;16(4):395–406. doi:10.1517/14728222.2012.66975222439677
   PubMed Web of Science ®Google Scholar
• Hakozaki T, Okuma Y, Hashimoto K, Hosomi Y. Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis. J Cancer Res Clin Oncol. 2019;145(10):2555–2564. doi:10.1007/s00432-019-02985-1.31350622
   PubMed Web of Science ®Google Scholar
• Malapelle U, Rossi A. Emerging angiogenesis inhibitors for non-small cell lung cancer. Expert Opin Emerg Drugs. 2019;24(2):71–81. doi:10.1080/14728214.2019.1619696.31092048
   PubMed Web of Science ®Google Scholar